Published in J Immunol on January 01, 1976
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun (1981) 2.49
Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun (1979) 1.94
Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection. Infect Immun (1982) 1.92
Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol (1977) 1.73
Antibody-mediated recovery from subcutaneous herpes simplex virus type 2 infection. Infect Immun (1978) 1.59
Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol (1980) 1.48
Mechanisms of recovery from Herpesvirus infections -a review. Can J Comp Med (1978) 1.34
Contrasting effects of immunosuppression on Theiler's virus infection in mice. Infect Immun (1977) 1.33
Lymphocyte reactivity contributes to protection conferred by specific antibody passively transferred to herpes simplex virus-infected mice. Infect Immun (1980) 1.32
Determination of herpes simplex virus type-specific antibodies by enzyme-linked immunosorbent assay. J Clin Microbiol (1983) 1.21
Human antibody-dependent cell-mediated cytotoxicity against target cells infected with respiratory syncytial virus. Clin Exp Immunol (1977) 1.18
Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes. J Exp Med (1977) 1.18
Cells that express viral antigens but lack H-2 determinants are not lysed by immune thymus-derived lymphocytes but are lysed by other antiviral immune attack mechanisms. Proc Natl Acad Sci U S A (1976) 1.17
Comparison of antibody-dependent cellular cytotoxicity and complement-dependent antibody lysis of herpes simplex virus-infected cells as methods of detecting antiviral antibodies in human sera. J Clin Microbiol (1977) 1.15
Effect of tunicamycin on the synthesis of herpes simplex virus type 1 glycoproteins and their expression on the cell surface. J Virol (1982) 1.14
Cell-mediated cytotoxicity to herpes-infected cells in humans: dependence on antibodies. Infect Immun (1977) 1.11
Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity. Infect Immun (1980) 1.08
Antibody-dependent cellular protection against herpes simplex virus dissemination as revealed by viral plauqe and infectivity assays. Infect Immun (1977) 1.03
Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody. Infect Immun (1979) 0.98
Reactivation of latent herpes simplex virus infection of the autonomic nervous system by postganglionic neurectomy. Infect Immun (1978) 0.98
Neutralization capacity and antibody dependent cell-mediated cytotoxicity of separated IgG subclasses 1, 3 and 4 against herpes simplex virus. Clin Exp Immunol (1988) 0.98
Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody. Infect Immun (1981) 0.97
Human antibody-dependent cellular cytotoxicity and natural killer cytotoxicity to herpes simplex virus-infected autologous and allogeneic cells. Immunology (1983) 0.96
Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia. J Virol (1984) 0.95
Detection of asymptomatic herpes simplex virus infections after vaccination. J Virol (1987) 0.93
Immunological reactivity of herpes simplex virus 1 and 2 polypeptides electrophoretically separated and transferred to diazobenzyloxymethyl paper. Infect Immun (1981) 0.91
Cellular and humoral immune responses to herpes simplex virus during and after primary gingivostomatitis. Infect Immun (1978) 0.88
Suppression of in vitro growth of virulent and avirulent herpes simplex viruses by cell-mediated immune mechanisms, antibody, and interferon. Infect Immun (1978) 0.84
Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation. Proc Natl Acad Sci U S A (1979) 0.83
Leukocyte cytotoxicity in a persistent virus infection: presence of direct cytotoxicity but absence of antibody-dependent cellular cytotoxicity in horses infected with equine infectious anemia virus. Infect Immun (1979) 0.83
Antibody-dependent cell-mediated cytotoxicity to Varicella zoster. Clin Exp Immunol (1984) 0.83
Lysis of herpes simplex virus-infected cells early in the infectious cycle by human antiviral antibody and complement. Infect Immun (1981) 0.82
Heterogeneity of human lymphocyte Fc receptors. II. Relationship to antibody-dependent, cell-mediated cytotoxicity. Clin Exp Immunol (1978) 0.82
Murine cellular cytotoxicity to syngeneic and xenogeneic herpes simplex virus-infected cells. Infect Immun (1982) 0.81
Effect of herpes simplex virus infection on murine antibody-dependent cellular cytotoxicity and natural killer cytotoxicity. Infect Immun (1981) 0.80
Immunogenic proteins of feline rhinotracheitis virus. J Virol (1984) 0.79
In vitro studies on the mechanism of herpesvirus plaque growth inhibition by sensitized lymphocytes. Infect Immun (1977) 0.78
Analysis of the lytic step in the herpes simplex virus antibody-dependent cellular cytotoxicity system. Infect Immun (1980) 0.78
Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells. Br J Exp Pathol (1986) 0.78
Analysis of the adhesion step in the herpes simplex virus antibody-dependent cellular cytotoxicity system. Infect Immun (1979) 0.77
Immune response in rabbits to surface components of extracellular and intracellular forms of vaccinia virus. Infect Immun (1980) 0.76
Natural cytotoxic cell activity linked to time of recurrence of herpes labialis. Clin Exp Immunol (1984) 0.75
Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med (1997) 7.59
Ampicillin-resistant Haemophilus influenzae type B infection. JAMA (1974) 5.90
Association of antigenic type of Herpesvirus hominis with site of viral recovery. J Immunol (1967) 5.07
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Infection with herpes-simplex viruses 1 and 2. 3. N Engl J Med (1973) 3.89
Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA (1988) 3.89
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998) 3.69
A trial of topical acyclovir in genital herpes simplex virus infections. N Engl J Med (1982) 3.66
The natural history of herpes simplex virus infection of mother and newborn. Pediatrics (1980) 3.65
Prevalence of psychiatric disorders in youths across five sectors of care. J Am Acad Child Adolesc Psychiatry (2001) 3.59
Comparative study of diagnostic procedures for congenital cytomegalovirus infection. Pediatrics (1980) 3.53
Prevalence of adolescent substance use disorders across five sectors of care. J Am Acad Child Adolesc Psychiatry (2001) 3.39
Antigenic and biologic differences in herpesvirus hominis. Prog Med Virol (1968) 3.31
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med (1989) 2.94
Herpesviridae. Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on Taxonomy of Viruses. Intervirology (1981) 2.92
Infection with herpes-simplex viruses 1 and 2. 1. N Engl J Med (1973) 2.87
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections. Am J Epidemiol (1970) 2.83
Immunity to influenza in ferrets. I. Response to live and killed virus. Br J Exp Pathol (1972) 2.78
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics (1980) 2.70
Herpes simplex virus encephalitis: laboratory evaluations and their diagnostic significance. J Infect Dis (1982) 2.70
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Typing of Herpesvirus hominis strains by a direct immunofluorescent technique. Proc Soc Exp Biol Med (1969) 2.64
Infection of the newborn with herpesvirus hominis. Adv Pediatr (1970) 2.61
Detection of cell-dependent cytotoxic antibody to cells infected with herpes simplex virus. Nature (1974) 2.55
Detection of herpes simplex virus type 2-specific antibody with glycoprotein G. J Clin Microbiol (1985) 2.54
Cytology and histopathology of cervical herpes simplex infection. Cancer (1966) 2.52
Different patterns of neurologic involvement with herpes simplex virus types 1 and 2: isolation of herpes simplex virus type 2 from the buffy coat of two adults with meningitis. J Infect Dis (1973) 2.52
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Perinatal risk associated with maternal genital herpes simplex virus infection. Am J Obstet Gynecol (1971) 2.40
Genital infection with type 2 Herpes virus hominis. A commonly occurring venereal disease. Br J Vener Dis (1969) 2.40
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Relation of pock size on chorioallantoic membrane to antigenic type of herpesvirus hominis. Proc Soc Exp Biol Med (1968) 2.34
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Herpes simplex virus infection as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis (1992) 2.25
Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci U S A (1998) 2.22
Human monocyte-macrophage-mediated antibody-dependent cytotoxicity to herpes simplex virus-infected cells. J Immunol (1977) 2.21
Antibodies to Herpesvirus hominis types 1 and 2 in humans. II. Women with cervical cancer. Am J Epidemiol (1970) 2.15
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
A community surveillance system of infectious diseases in the greater Atlanta area. Am J Public Health Nations Health (1966) 2.11
Inhibitory effect of heparin on herpes simplex virus. J Bacteriol (1964) 2.11
Genital herpetic infection. Association with cervical dysplasia and carcinoma. Cancer (1969) 2.10
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Genital herpes simplex infection. Virologic and cytologic studies. Obstet Gynecol (1967) 1.95
Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases. Am J Pathol (2001) 1.94
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet (2001) 1.93
Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev (2004) 1.90
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Demonstration of exogenous genital reinfection with herpes simplex virus type 2 by restriction endonuclease fingerprinting of viral DNA. J Infect Dis (1979) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Quantitative analysis of genomic polymorphism of herpes simplex virus type 1 strains from six countries: studies of molecular evolution and molecular epidemiology of the virus. J Gen Virol (1994) 1.79
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Transcriptional control of a nuclear gene encoding a mitochondrial fatty acid oxidation enzyme in transgenic mice: role for nuclear receptors in cardiac and brown adipose expression. Mol Cell Biol (1996) 1.73
Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells. Clin Exp Immunol (1977) 1.73
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
Immunity to influenza in ferrets. II. Influence of adjuvants on immunization. Br J Exp Pathol (1972) 1.70
A cross-sectional study of herpes simplex virus types 1 and 2 in college students: occurrence and determinants of infection. J Infect Dis (1990) 1.70
Antigens of Herpes simplex virus type 1 and 2-immunodiffusion and inhibition passive hemagglutination studies. Z Immunitatsforsch Exp Klin Immunol (1971) 1.67
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
Type-specific surface antigens of cells infected with herpes simplex virus (1 and 2). Proc Soc Exp Biol Med (1971) 1.64
Infection with herpes-simplex viruses 1 and 2. II. N Engl J Med (1973) 1.64
Early progression of disease in HIV-infected infants with thymus dysfunction. N Engl J Med (1996) 1.63
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Fc receptors for IgE on a subpopulation of human peripheral blood monocytes. J Immunol (1980) 1.59
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology (1994) 1.54
The use of infra-red thermography in a rheumatology unit. Br J Rheumatol (1990) 1.53
The structure of herpes simplex virus DNA and its application to molecular epidemiology. Ann N Y Acad Sci (1980) 1.52
The epidemiology of Type 2 (genital) herpes simplex virus infection. Obstet Gynecol Surv (1972) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Filamentous structures of type 2 Herpesvirus hominis infection of the chorioallantoic membrane. J Virol (1969) 1.50